Therapeutic insights: Use of ceftazidime‐avibactam in pediatric patients
Pediatrics International · 2024-01 · 66 (1)
DOI: 10.1111/ped.15787 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pediatrics International, 2024-08. Verfasst von Özge Metin Akcan und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatric Infectious Diseases, Meram Faculty of Medicine, Necmettin Erbakan University, Konya, Turkey. Hauptthemen laut MEDLINE: Ceftazidime, Azabicyclo Compounds, Drug Combinations, Anti-Bacterial Agents. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 16 Literaturangaben.
Abstract (Originalsprache)
Background
The increasing worldwide prevalence of multidrug‐resistant (MDR) bacteria underscores the pressing demand for innovative therapeutic solutions. Ceftazidime‐avibactam (CAZ‐AVI) represents a promising new drug combination that has received approval for specific infection types. However, there is limited information regarding its application in pediatric patients.
Methods
This study investigates the effectiveness and adverse reactions associated with CAZ‐AVI treatment in pediatric patients with life‐threatening infections caused by MDR pathogens. The study was conducted at a tertiary children's hospital between December, 2021 and July, 2023.
Results
A total of 21 patients with life‐threatening infections caused by MDR pathogens were enrolled in the study. All patients had underlying medical conditions: 10 had cerebral palsy, four had congenital neurometabolic disease, two had Nieman–Pick disease, two had cystic fibrosis, two had primary immunodeficiency, and one had leukemia. Among these, 12 patients had tracheostomies. Eight patients received CAZ‐ AVI monotherapy, and 13 patients received combination therapy. Microbiological eradication was achieved in 18 patients (85.7%), and a clinical response was observed in 20 patients (95.2%). Two patients (9.5%) experienced relapse with the same bacteria. One patient developed anaphylaxis, and one patient had elevated creatine phosphokinase levels that normalized following discontinuation of treatment. One patient died during the study period due to gastrointestinal bleeding.
Conclusions
Ceftazidime‐avibactam may be a promising new drug option for the treatment of life‐threatening infections caused by MDR Gram‐negative microorganisms in pediatric patients. However, further studies with larger case series are needed to further evaluate the efficacy and safety of CAZ‐AVI in this population.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pediatric Infectious Diseases, Meram Faculty of Medicine, Necmettin Erbakan University, Konya, Turkey.
- Department of Pediatrics, Meram Faculty of Medicine, Necmettin Erbakan University, Konya, Turkey.
- Department of Pediatric Pulmonology, Meram Faculty of Medicine, Necmettin Erbakan University, Konya, Turkey.
- Department of Medical Microbiology, Meram Faculty of Medicine, Necmettin Erbakan University, Konya, Turkey.
ORCID-Profile: Özge Metin Akcan, Mustafa Gençeli
Zitieren
APA
Akcan, Ö. M., Gençeli, M., Üstüntaş, T., Akkuş, A., Pekcan, S., & Doğan, M. (2024). Therapeutic insights: Use of ceftazidime‐avibactam in pediatric patients. Pediatrics International, 66(1). https://doi.org/10.1111/ped.15787
Vancouver
Akcan ÖM, Gençeli M, Üstüntaş T, Akkuş A, Pekcan S, Doğan M. Therapeutic insights: Use of ceftazidime‐avibactam in pediatric patients. Pediatrics International. 2024;66(1). doi:10.1111/ped.15787
BibTeX
@article{Akcan2024,
author = {Akcan, Özge Metin and Gençeli, Mustafa and Üstüntaş, Talha and Akkuş, Abdullah and Pekcan, Sevgi and Doğan, Metin},
title = {Therapeutic insights: Use of ceftazidime‐avibactam in pediatric patients},
journal = {Pediatrics International},
year = {2024},
volume = {66},
number = {1},
doi = {10.1111/ped.15787}
}
EUVIMED